4.10Open4.10Pre Close0 Volume1 Open Interest5.00Strike Price0.00Turnover642.01%IV14.29%PremiumMay 16, 2025Expiry Date3.95Intrinsic Value100Multiplier16DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.6944Delta0.2533Gamma0.26Leverage Ratio-0.0152Theta-0.0015Rho-0.18Eff Leverage0.0008Vega
Sutro Biopharma Stock Discussion
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
Monday, 28th April at 4:05 pm
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (...
Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future
Sutro Biopharma Unveils Major Strategic Shift with $317M War Chest Through 2026
Boehringer Ingelheim And Sutro Biopharma Announced Successful Large-Scale Production Of Luvelta Using Sutro's Cell-Free Expression Technology For Ovarian Cancer Treatment; Achieved Industry Milestone With 4,500L GMP Batches Meeting Clinical Study...
No comment yet